Research Analysts Set Expectations for DGX FY2025 Earnings

Quest Diagnostics Incorporated (NYSE:DGX) – Analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of Quest Diagnostics in a research report issued to clients and investors on Tuesday, November 11th. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $9.77 per share for the year, up from their prior forecast of $9.73. The consensus estimate for Quest Diagnostics’ current full-year earnings is $9.70 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.34 EPS, Q2 2026 earnings at $2.76 EPS, Q4 2026 earnings at $2.47 EPS and Q2 2027 earnings at $2.82 EPS.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, October 21st. The medical research company reported $2.60 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.09. The firm had revenue of $2.82 billion for the quarter, compared to analysts’ expectations of $2.73 billion. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.The company’s quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.30 earnings per share. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS.

Other research analysts also recently issued research reports about the stock. Mizuho increased their price objective on shares of Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Wall Street Zen lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “buy (b)” rating on shares of Quest Diagnostics in a research report on Wednesday, October 8th. Morgan Stanley set a $207.00 target price on Quest Diagnostics and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Leerink Partners boosted their price target on Quest Diagnostics from $203.00 to $210.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus target price of $196.31.

Quest Diagnostics Stock Performance

Shares of DGX opened at $188.85 on Wednesday. Quest Diagnostics has a 12 month low of $148.70 and a 12 month high of $197.55. The business’s fifty day simple moving average is $182.60 and its two-hundred day simple moving average is $178.04. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. The company has a market cap of $21.01 billion, a price-to-earnings ratio of 22.17, a P/E/G ratio of 2.31 and a beta of 0.58.

Hedge Funds Weigh In On Quest Diagnostics

A number of institutional investors have recently modified their holdings of DGX. Pinnacle Bancorp Inc. grew its stake in Quest Diagnostics by 126.9% in the second quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock worth $27,000 after purchasing an additional 85 shares in the last quarter. True Wealth Design LLC grew its position in shares of Quest Diagnostics by 369.7% during the 3rd quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares in the last quarter. MTM Investment Management LLC purchased a new position in shares of Quest Diagnostics during the second quarter valued at $29,000. First Horizon Corp purchased a new position in shares of Quest Diagnostics during the third quarter valued at $33,000. Finally, AlphaQuest LLC raised its holdings in shares of Quest Diagnostics by 18,400.0% in the second quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 184 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Michael E. Prevoznik sold 227 shares of the firm’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $188.13, for a total value of $42,705.51. Following the completion of the sale, the senior vice president owned 38,117 shares in the company, valued at approximately $7,170,951.21. This trade represents a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Patrick Plewman sold 1,975 shares of the firm’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $185.00, for a total transaction of $365,375.00. Following the completion of the sale, the senior vice president directly owned 15,269 shares of the company’s stock, valued at approximately $2,824,765. The trade was a 11.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,654 shares of company stock valued at $7,189,232 over the last ninety days. 8.16% of the stock is owned by insiders.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics’s payout ratio is presently 37.56%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.